权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mentoring and Research in Patient-Oriented Cardiovascular Pharmacoepidemiology

以患者为中心的心血管药物流行病学的指导和研究

基本信息

批准号：
10657650
负责人：
PAMELA L. Lutsey
金额：
$ 10.42万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10657650
关键词：
Acceleration Address Adult Adverse event Anticoagulants Area Atherosclerosis Risk in Communities Atrial Fibrillation Behavioral Cancer Patient Cardiovascular Diseases Cardiovascular system Characteristics Clinical Clinical Investigator Comparative Effectiveness Research Complex Data Data Sources Disease Outcome Drug Interactions Drug usage Effectiveness Elderly Environment Ethnic Origin Funding Genes Glean Guidelines Heart failure Hypertension Individual Intervention Kidney Diseases Knowledge Lead Learning Malignant Neoplasms Manuscripts Medicare Mentors Mentorship Methodology Methods Mid-Career Clinical Scientist Award (K24)Minnesota Multi-Ethnic Study of Atherosclerosis Oral Outcome Participant Patients Pharmaceutical Preparations Pharmacoepidemiology Pharmacologic Substance Pharmacological Treatment Pharmacotherapy Phenotype Physiological Play Polypharmacy Population Populations at Risk Prevalence Prevention Principal Investigator Proteomics Publishing Quality of Care Race Randomized, Controlled Trials Recurrence Research Research Activity Research Methodology Research Personnel Risk Reduction Role Sample Size Sampling Scientific Advances and Accomplishments Structure Supervision Survivors Techniques Testing Time Training Translational Research Universities adverse outcome burden of illness cardiovascular disorder epidemiology cardiovascular disorder risk career career development clinical epidemiology clinical practice clinically significant cohort comparative effectiveness complex data diabetes control effectiveness evaluation effectiveness research experience flexibility graduate student health literacy human old age (65+)improved improved outcome interest medication compliance multiple chronic conditions novel patient oriented patient oriented research patient population pharmacologic post-market prevent programs prospective pulmonary arterial hypertension recruit response rural disparities skill acquisition student participation training opportunity treatment strategy venous thromboembolism

项目摘要

SUMMARY This application will provide the Principal Investigator, Dr. Pamela Lutsey, with protected time and other support to 1) accelerate a successful record of mentoring junior clinical investigators and graduate students engaged in cardiovascular disease (CVD) patient-oriented research (POR), 2) obtain additional training in pharmacoepidemiology, -omics and mentoring best practices and 3) advance her ongoing CVD pharmacoepidemiology research program. Pharmaceuticals play a crucial role in the prevention and treatment of CVD and other conditions. To improve the effectiveness of pharmacologic interventions on CVD outcomes, we need junior clinical investigators conducting POR who have rigorous training and mentorship in the areas of pharmacoepidemiology, clinical epidemiology of CVD, translational research methods and the use of complex data sources. An expert in these areas, the candidate, Dr. Lutsey, proposes to apply K24 funds toward the mentorship of POR scholars at the University of Minnesota who are committed to a research career that will reduce the burden of CVD in the population through building rigorous evidence regarding how to optimize use of pharmaceuticals in order to prevent CVD in at-risk populations and reduce risk of recurrence among individuals with CVD. Aim 1 involves conducting pharmacoepidemiology POR comparative effectiveness research to prevent CVD in at-risk populations and improve the outcomes among CVD survivors. State-of-the-art pharmacoepidemiologic techniques will be applied to large administrative data sources, specifically MarketScan and the Medicare 20% sample. Aim 2 will harness rich data from deeply phenotyped cohorts to understand behavioral characteristics that influence the effectiveness of medications, and glean added understanding of the physiologic mechanisms through which pharmacotherapies act. These analyses will use data from the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic Study of Atherosclerosis (MESA). Findings from the proposed Aims will advance understanding of the role of specific pharmacologic treatment strategies on CVD risk, and have potential to directly impact clinical practice, reinforcing or leading to reconsideration of existing clinical guidelines. This proposal is structured to allow trainees the flexibility to pursue their own hypotheses, motivated by their clinical experiences and interests. With support from this K24, Dr. Lutsey plans to expand the breadth of her POR research activities, recruit new junior clinical scholars into POR, and prepare them to make major scientific advances and launch their own independent research careers.

总结

项目成果

期刊论文数量（27）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Performance of the pooled cohort equations in cancer survivors: the Atherosclerosis Risk in Communities study.

癌症幸存者中汇总队列方程的表现：社区动脉粥样硬化风险研究。

DOI：
10.1007/s11764-023-01379-0
发表时间：
2024
期刊：
Journal of cancer survivorship : research and practice
影响因子：
0
作者：
Polter,ElizabethJ;Blaes,Anne;Wolfson,Julian;Lutsey,PamelaL;Florido,Roberta;Joshu,CorinneE;Guha,Avirup;Platz,ElizabethA;Prizment,Anna
通讯作者：
Prizment,Anna

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.

DOI：
10.1002/cpt.2806
发表时间：
2023-02
期刊：
CLINICAL PHARMACOLOGY & THERAPEUTICS
影响因子：
6.7
作者：
Kumar, Arun;Lutsey, Pamela L.;St. Peter, Wendy L.;Schommer, Jon C.;Van't Hof, Jeremy R.;Rajpurohit, Abhijeet;Farley, Joel F.
通讯作者：
Farley, Joel F.

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study.

DOI：
10.1002/cpt.2797
发表时间：
2023-02
期刊：
CLINICAL PHARMACOLOGY & THERAPEUTICS
影响因子：
6.7
作者：
Kumar, Arun;Lutsey, Pamela L.;St Peter, Wendy L.;Schommer, Jon C.;Van't Hof, Jeremy R.;Rajpurohit, Abhijeet;Farley, Joel F.
通讯作者：
Farley, Joel F.

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data.

2021-2022 年 SGLT2i 和 ARNi 在心房颤动和心力衰竭患者中的使用：真实世界数据分析。

DOI：
10.1101/2023.09.08.23295280
发表时间：
2023
期刊：
medRxiv : the preprint server for health sciences
影响因子：
0
作者：
Alonso,Alvaro;Morris,AlannaA;Naimi,AshleyI;Alam,AniqaB;Li,Linzi;Subramanya,Vinita;Chen,LinYee;Lutsey,PamelaL
通讯作者：
Lutsey,PamelaL

Case-control studies: Increasing scientific rigor in control selection.